Aclaris Therapeutics (ACRS) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Aclaris Therapeutics (ACRS) over the last 7 years, with Q3 2025 value amounting to -$0.12.
- Aclaris Therapeutics' EPS (Weighted Average and Diluted) fell 909.09% to -$0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.58, marking a year-over-year decrease of 20384.62%. This contributed to the annual value of -$1.71 for FY2024, which is 3453.13% down from last year.
- Aclaris Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.12 in Q3 2025, which was down 909.09% from -$0.13 recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.02 during Q4 2023, and registered a low of -$1.26 during Q4 2024.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.31 (2022), whereas its average is -$0.33.
- In the last 5 years, Aclaris Therapeutics' EPS (Weighted Average and Diluted) surged by 9512.2% in 2023 and then crashed by 621152.72% in 2024.
- Quarter analysis of 5 years shows Aclaris Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.37 in 2021, then fell by 10.81% to -$0.41 in 2022, then skyrocketed by 95.12% to -$0.02 in 2023, then tumbled by 6211.53% to -$1.26 in 2024, then skyrocketed by 90.49% to -$0.12 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.12 for Q3 2025, versus -$0.13 for Q2 2025 and -$0.12 for Q1 2025.